NO20092360L - Nye antiproliferasjonsantistoffer - Google Patents

Nye antiproliferasjonsantistoffer

Info

Publication number
NO20092360L
NO20092360L NO20092360A NO20092360A NO20092360L NO 20092360 L NO20092360 L NO 20092360L NO 20092360 A NO20092360 A NO 20092360A NO 20092360 A NO20092360 A NO 20092360A NO 20092360 L NO20092360 L NO 20092360L
Authority
NO
Norway
Prior art keywords
antibodies
novel
relates
present
antiproliferation antibodies
Prior art date
Application number
NO20092360A
Other languages
English (en)
Norwegian (no)
Inventor
Liliane Goetsch
Nathalie Corvaia
Jean-Francois Haeuw
Cedrik Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NO20092360L publication Critical patent/NO20092360L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
NO20092360A 2006-11-24 2009-06-19 Nye antiproliferasjonsantistoffer NO20092360L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0610329A FR2909092B1 (fr) 2006-11-24 2006-11-24 Nouveaux anticorps anti-proliferation
PCT/EP2007/062760 WO2008062063A1 (en) 2006-11-24 2007-11-23 Novel antiproliferation antibodies

Publications (1)

Publication Number Publication Date
NO20092360L true NO20092360L (no) 2009-08-11

Family

ID=37903981

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20092360A NO20092360L (no) 2006-11-24 2009-06-19 Nye antiproliferasjonsantistoffer

Country Status (27)

Country Link
US (2) US8071730B2 (enExample)
EP (1) EP2074148A1 (enExample)
JP (1) JP2010509931A (enExample)
KR (1) KR20090088878A (enExample)
CN (1) CN101535344B (enExample)
AU (1) AU2007324509B2 (enExample)
BR (1) BRPI0719323A2 (enExample)
CA (1) CA2670039A1 (enExample)
CL (1) CL2007003357A1 (enExample)
CR (1) CR10788A (enExample)
CU (1) CU23792A3 (enExample)
EC (1) ECSP099341A (enExample)
FR (1) FR2909092B1 (enExample)
GE (1) GEP20125629B (enExample)
GT (1) GT200900126A (enExample)
IL (1) IL198744A0 (enExample)
MA (1) MA30891B1 (enExample)
MX (1) MX2009005293A (enExample)
NI (1) NI200900079A (enExample)
NO (1) NO20092360L (enExample)
NZ (1) NZ576174A (enExample)
RU (1) RU2451689C2 (enExample)
SA (1) SA07280637B1 (enExample)
TN (1) TN2009000194A1 (enExample)
TW (1) TW200829602A (enExample)
UA (1) UA99602C2 (enExample)
WO (1) WO2008062063A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
WO2010002862A2 (en) * 2008-07-01 2010-01-07 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (fgfr3) binding proteins
CA2777698A1 (en) * 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax1 and ax189 pcsk9 antagonists and variants
CA2815277A1 (en) * 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130287790A1 (en) * 2012-03-30 2013-10-31 The Board Of Trustees Of The Leland Standford Junior University Use of jam-a in diagnosing and treating leukemia
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
KR20150097304A (ko) 2014-02-18 2015-08-26 삼성전자주식회사 항 EGFR DARPin을 포함하는 EGFR/HER2 이중 특이 항체
RU2756275C2 (ru) 2016-03-01 2021-09-29 Юссум Рисёрч Девелопмент Компани Оф Зэ Хибру Юниверсити Оф Иерусалим Лтд. Антитела, специфические к рецептору полиовируса (pvr) человека
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
CA3032826A1 (en) * 2016-08-03 2018-02-08 Nextcure, Inc. Compositions and methods for modulating lair signal transduction
CN109022366A (zh) * 2018-08-16 2018-12-18 江南大学 一株分泌抗左旋咪唑单克隆抗体的杂交瘤细胞株及其应用
KR20220082007A (ko) 2019-10-08 2022-06-16 넥틴 테라퓨틱스 리미티드 폴리오바이러스 수용체(pvr)에 대한 항체 및 이의 용도
CN114740108B (zh) * 2022-03-28 2023-07-14 天津键凯科技有限公司 一种聚合物修饰抗体类药物的修饰度的测定方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US20030171568A1 (en) * 1998-09-16 2003-09-11 Avi Ashkenazi Use of A33 antigens and JAM-IT
SK14812000A3 (sk) * 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
MXPA01009110A (es) * 1999-03-11 2002-08-20 Rmf Dictagene Sa Moleculas de adhesion vascular y modulacion de su funcion.
EP1708961B1 (en) * 2003-12-04 2011-03-09 Abbott Biotherapeutics Corp. Anti-ip-10 antibodies
WO2006008076A2 (en) * 2004-07-16 2006-01-26 Universita Degli Studi Di Milano Methods and agents stimulating the immune response
WO2006121207A1 (en) * 2005-05-12 2006-11-16 Oncotherapy Science, Inc. Methods for damaging cells using effector function of anti-dsc2 antibody
EP2021371A2 (en) * 2006-04-28 2009-02-11 Oregon Health and Science University Monoclonal antibodies specific for pancreatic endocrine, exocrine or ductal cells

Also Published As

Publication number Publication date
NI200900079A (es) 2010-11-10
CA2670039A1 (en) 2008-05-29
AU2007324509B2 (en) 2013-01-17
TN2009000194A1 (en) 2010-10-18
SA07280637B1 (ar) 2012-04-11
KR20090088878A (ko) 2009-08-20
HK1132752A1 (en) 2010-03-05
CL2007003357A1 (es) 2008-04-04
CN101535344B (zh) 2013-10-16
MX2009005293A (es) 2009-08-07
AU2007324509A1 (en) 2008-05-29
GT200900126A (es) 2011-09-02
JP2010509931A (ja) 2010-04-02
GEP20125629B (en) 2012-09-10
RU2009123409A (ru) 2010-12-27
TW200829602A (en) 2008-07-16
US20100092455A1 (en) 2010-04-15
RU2451689C2 (ru) 2012-05-27
FR2909092B1 (fr) 2012-10-19
CR10788A (es) 2009-06-23
US8071730B2 (en) 2011-12-06
CU23792A3 (es) 2012-03-15
WO2008062063A1 (en) 2008-05-29
FR2909092A1 (fr) 2008-05-30
ECSP099341A (es) 2009-06-30
EP2074148A1 (en) 2009-07-01
MA30891B1 (fr) 2009-11-02
UA99602C2 (ru) 2012-09-10
CN101535344A (zh) 2009-09-16
NZ576174A (en) 2012-03-30
US20120156191A1 (en) 2012-06-21
BRPI0719323A2 (pt) 2014-02-04
IL198744A0 (en) 2010-02-17

Similar Documents

Publication Publication Date Title
TN2009000194A1 (en) Novel antiproliferation antibodies
UA102867C2 (uk) Антитіла до cxcr4 та їх застосування у лікуванні раку
NO20084396L (no) Kombinasjonsterapi
NO20092285L (no) Humane, monoklonale antistoffer til BTLA og fremgangsmater for anvendelse
NO20081987L (no) Humane, monoklonale antistoffer mot CD70
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
NZ754051A (en) Novel antibodies and uses thereof
CY1118977T1 (el) Επιτοποι σκληροστινης
EA201170659A1 (ru) Антитела к рецептору ii tgf-вета
UA97516C2 (ru) Полностью человеческое моноклональное антитело против vap-1
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
DE602005027258D1 (de) Humane monoklonale antikörper gegen hendra- und nipah-viren
EA200801571A1 (ru) Композиции, содержащие молекулы ctl4-ig, и способы их получения
NO20074446L (no) DR5-antistoffer og anvendelser derav
TW200740844A (en) Novel MAdCAM antibodies
PH12012501934A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
MEP53308A (en) Novel peptides that bind to the erythropoietin receptor
MY151036A (en) Synthesis of (r)-n-methylnaltrexone
NO20083053L (no) Humane monoklonale antistoffer mot O8E
BR112012007860A2 (pt) "anticorpos siglec 15 no tratamento de doença relativa a perda óssea"
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
NO20076401L (no) Diarylhydantoinforbindelser
WO2008027739A3 (en) Antibodies to ntb-a
EA201170590A1 (ru) Ингибиторы рецептора фактора роста фибробластов-3 (fgfr-3) и способы лечения
MX2010002716A (es) Uso de slit, nefrina, efrina o semaforina para el tratamiento de enfermedades de cartilago.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application